Viridian Therapeutics (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing drug candidates for serious diseases. The company does not yet generate product revenue, operating instead on capital raised through equity financings to fund research and development. The 10-K filed 2026-02-26 (accession 000159075026000007) identifies Viridian as a well-known seasoned issuer, but the filing excerpts provided do not contain sufficient detail to characterize specific pipeline assets, therapeutic areas, clinical stage, partnerships, leadership, founding year, headquarters, or competitive positioning. A complete business description requires review of the full filing body, which was not included in the excerpts supplied.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Arcellx Inc Coherus Oncology Inc IGM Biosciences, Inc. MannKind Corp Mirum Pharmaceuticals Inc Northwest Biotherapeutics Inc Replimune Group Inc Sangamo Therapeutics Inc Seres Therapeutics Inc